Brady L W
Department of Radiation Oncology, Allegheny University of the Health Sciences Allegheny University Hospitals, Hahnemann, Philadelphia, USA.
Bull Mem Acad R Med Belg. 1998;153(5-6):255-61; discussion 261-2.
The data confirmed the fact that repeated administrations of iodine-125 labeled anti-epidermal growth factor receptor 425 is safe and may have benefited the management of primary high grade gliomas of the brain as well as recurrent astrocytomas. At present, a randomized control phase III trial is in the process of being initiated to evaluate the benefits that would accrue in a controlled environment.
重复给予碘-125标记的抗表皮生长因子受体425是安全的，并且可能有助于原发性高级别脑胶质瘤以及复发性星形细胞瘤的治疗。目前，一项随机对照III期试验正在启动过程中，以评估在可控环境中可能产生的益处。
